THE MYELOMA CANCER DIARIES

Select other agents are encouraged as option agents depending on administration difficulties and/or adverse effect profile.  Zidovudine combined with lamivudine is the choice NRTI backbone but is linked to extra hematologic toxicity. Lopinavir/ritonavir is an alternate PI agent with proven safety but exhibits increased gastrointestinal intolerance